IL-33 antibody

Catalog No. ABIN1169164

Product Details anti-IL-33 Antibody

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Reactivity: Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This IL-33 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Specificity: Recognizes mouse IL-33. Detects a band of ~18 kDa by Western blot.

Cross-Reactivity: Mouse (Murine)

No Cross-Reactivity: Human

Cross-Reactivity (Details): Does not cross-react with human IL-33.

Sterility: 0.2 μm filtered

Immunogen: Recombinant mouse IL-33.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.

Preservative: Without preservative

Storage: 4 °C,-20 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 6 months after receipt when stored at -20°C.

Expiry Date: 6 months

References for anti-IL-33 antibody (ABIN1169164)

Hayakawa, Hayakawa, Kume, Tominaga: "Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation." in: The Journal of biological chemistry, Vol. 282, Issue 36, pp. 26369-80, (2007) (PubMed).

Target Details for IL-33

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Alternative Name: IL-33 (IL33 Products)

Synonyms: IL33 antibody, C9orf26 antibody, DVS27 antibody, IL1F11 antibody, NF-HEV antibody, NFEHEV antibody, RP11-575C20.2 antibody, 9230117N10Rik antibody, Il-33 antibody, Il1f11 antibody, RGD1311155 antibody, interleukin 33 antibody, IL33 antibody, Il33 antibody

Background: Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30 kDa human IL33 is converted by CASP1 to a 18 kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1(MAPK3)/ERK2(MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.

UniProt: Q8BVZ5

Pathways: Production of Molecular Mediator of Immune Response